NLRP3 and endothelial dysfunction: To better understand how raltegravir alleviates LPS-induced endothelial dysfunction and whether such activity is linked to NLRP3 inflammasome or NF-κB activity, these cells were treated with the NLRP3 inhibitor MCC950 or the NF-κB inhibitor BAY11-7082.